High‐Load Gemcitabine Inorganic–Organic Hybrid Nanoparticles as an Image‐Guided Tumor‐Selective Drug‐Delivery System to Treat Pancreatic Cancer

Abstract

Pancreatic ductal adenocarcinoma (PDAC) has a devastating prognosis without effective treatment options. Thus, there is an urgent need for more effective and safe therapies. Here, we present inorganic‐organic hybrid nanoparticles (GMP‐IOH‐NPs) as novel drug‐delivery system for the selective delivery of extraordinarily high concentrations of gemcitabine monophosphate (GMP) not only to the primary tumor but also to metastatic sites. GMP‐IOH‐NPs have a composition [ZrO]2+[GMP]2– with GMP as drug anion (76% of total IOH‐NP mass). Multiscale fluorescence imaging confirms an efficient uptake in tumor cells, independent of the activity of the human‐equilibrative‐nucleoside transporter (hENT1), being responsible for gemcitabine (GEM) transport into cells and a key factor for GEM resistance. Delivering already phosphorylated GMP via GMP‐IOH‐NPs into tumor cells also allows to overcome cellular resistance induced by the down‐regulation of deoxycytidine kinase. GMP‐IOH‐NPs show high accumulation in tumor lesions and only minor liver trapping when given intraperitoneally. GMP‐IOH‐NPs result in a higher anti‐tumor efficacy compared to free GEM and is further enhanced applying cetuximab‐functionalized GMP‐CTX‐IOH‐NPs. By maximizing the therapeutic benefits with high drug load, tumor‐specific delivery, minimizing undesired side effects, overcoming mechanisms of chemoresistance, and preventing systemic GEM inactivation, we anticipate GMP‐IOH‐NPs to have a high chance to significantly improve current PDAC‐patient outcome.This article is protected by copyright. All rights reserved

Inhibition of Histone Deacetylase Activity Increases Cisplatin Efficacy to Eliminate Metastatic Cells in Pediatric Liver Cancers

“…The inhibition of DNA replication by anti-cancer drug gemcitabine parallels the inhibition of CAFs and blocks the formation of tumor clusters in cells derived from lung metastases. Gemcitabine is an FDA-approved inhibitor of DNA replication and effectively kills cancer cells by increasing apoptosis [24][25][26]. We found that in a low-density setting, LM81 cells treated with gemcitabine (5 nM) do not form tumor clusters, compared to DMSO-treated cells (Figure 9A).…”

Cocktail of lipophilic and hydrophilic chemotherapeutics in high-load core@shell nanocarriers to treat pancreatic tumours

“…We have observed similar intracellular localization patterns also for other, comparable types of nanocarriers, suggesting an endocytic internalization pathway with late endosomal/lysosomal localization after 24 and 48 h, respectively. 25 …”

A Curated Cell Life Imaging Dataset of Immune-enriched Pancreatic Cancer Organoids with Pre-trained AI Models

“…To generate murine PDAC tumors, a quantity of 5 × 10 5 KPC cells was orthotopically implanted into the pancreatic head of C57BL/6 J mice, following previously established procedures 21 . Murine peripheral blood was collected from euthanized healthy C57BL/6J mice through cardiac puncture.…”